↓ Skip to main content

Immunotherapeutic Advancements for Glioblastoma

Overview of attention for article published in Frontiers in oncology, January 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
4 X users

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Immunotherapeutic Advancements for Glioblastoma
Published in
Frontiers in oncology, January 2015
DOI 10.3389/fonc.2015.00012
Pubmed ID
Authors

Leonel Ampie, Eric C. Woolf, Christopher Dardis

Abstract

Immunotherapy seeks to improve the body's immune response to a tumor. Currently, the principal mechanisms employed are: (1) to improve an aspect of the immune response (e.g., T cell activation) and (2) to encourage the targeting of particular antigens. The latter is typically achieved by exposing the immune system to the antigen in question, in vivo, or in vitro followed by re-introduction of the primed cells to the body. The clinical relevance of these approaches has already been demonstrated for solid tumors such as melanoma and prostate cancer. The central nervous system was previously thought to be immune privileged. However, we know now that the immune system is highly active in the brain and interacts with brain tumors. Thus, harnessing and exploiting this interaction represents an important approach for treating malignant brain tumors. We present a summary of progress in this area, focusing particularly on immune-checkpoint inhibition, vaccines, and T cell engineering.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Portugal 1 1%
France 1 1%
Brazil 1 1%
India 1 1%
Korea, Republic of 1 1%
Spain 1 1%
Unknown 94 94%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 22%
Researcher 16 16%
Student > Master 14 14%
Student > Bachelor 12 12%
Other 8 8%
Other 11 11%
Unknown 17 17%
Readers by discipline Count As %
Medicine and Dentistry 23 23%
Biochemistry, Genetics and Molecular Biology 20 20%
Agricultural and Biological Sciences 16 16%
Neuroscience 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 14 14%
Unknown 18 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2015.
All research outputs
#14,277,392
of 25,373,627 outputs
Outputs from Frontiers in oncology
#3,523
of 22,416 outputs
Outputs of similar age
#174,816
of 361,618 outputs
Outputs of similar age from Frontiers in oncology
#32
of 92 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 361,618 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.